tw0122
2 weeks ago
Looking good today $1.23 + 50%
NEW YORK--(BUSINESS WIRE)--Jan. 14, 2025--Market News Alerts Updates that DarioHealth Corp. (Nasdaq: DRIO) is taking another bold step into the rapidly growing weight-loss market, now projected to exceed $100 billion annually by 2030. The companyās latest move expands its GLP-1 offering with prescribing capabilities, positioning Dario to capture a larger share of this lucrative space as demand for medical weight-loss solutions skyrockets across employers and consumers. Following the announcement, Darioās shares surged nearly 14%, reflecting investor excitement over this significant growth opportunity.The market for GLP-1 medications, driven by blockbuster drugs like Novo Nordiskās Ozempic and Wegovy, is transforming how obesity and weight management are addressed. These medications have shown impressive results, leading to double-digit weight loss, but the rising costs are pushing employers to seek solutions that ensure better ROI. With 44% of large employers now covering obesity medications, according to a recent Mercer survey, Darioās expanded offering provides an end-to-end program to improve employee health outcomes while managing costs.Unlike many digital health providers, Darioās solution integrates behavior change programs with physician oversight, ensuring that GLP-1 medications are prescribed to the right people and supported by sustainable lifestyle changes. This approach aims to prevent the all-too-common cycle of weight regain after medication use, a key concern for both individuals and employers. The new prescribing capability is a critical piece of the puzzle, enabling Dario to oversee the entire weight-loss journey and optimize long-term results.Beyond employers, the direct-to-consumer market is another high-growth target for Dario. As more consumers seek out medical weight-loss options online, the companyās digital platform, combined with virtual care, offers an easily accessible, scalable solution to meet this demand. Additionally, pharmaceutical companies are increasingly seeking partners like Dario to provide data-driven insights and improve patient engagement, opening potential new revenue streams.Darioās move follows the success of GLP-1 giants Novo Nordisk and Eli Lilly, whose treatments have reshaped the market. However, while the market leaders focus on medications alone, Darioās behavior-first model differentiates it by tackling the underlying habits that drive lasting weight loss.As the GLP-1 market continues to expand, Darioās integrated solution could position the company as a key digital health partner for employers, consumers, and pharma companies alikeātapping into one of healthcareās most promising opportunities for growth.Market Alerts are generated by Wall Street Wireās news desk and summarize news developments. They include partner content on behalf of the mentioned issuer [DRIO]. They are not intended to serve as financial or investment advice. Please see our full terms, disclaimers and compensation disclosures here: redditwire.com/terms. Our alerts may include forward looking statements about the significance or impact an announcement or development may have on the future of a company or industry as well as other similar statements which may not come to fruition. We advise all readers refer to our full terms in the above link.View source version on businesswire.com: https://www.businesswire.com/news/home/20250114486200/en/Market Alerts News Desk
media.globalmarkets@gmail.com
PennyStockTrader2
1 year ago
wow look at DRIO, it totally collapsed, I ended up doing pretty decent considering its fall from grace even down to 3 bucks, but, the scary part is had I had enough free cash to buy back in from say $3 to $1 I would probably have done so, this is just utter devastation of a stock that has real revenues and real impact on peoples lives, I literally cannot believe it. At a buck it sure seems like a friggin steal
PennyStockTrader2
2 years ago
DRIOs been a tough trade for the last 10 months or so, but still have been able to make a few bucks overall, the stock long term is oversold compared to the rest of the market. Most recently I wrote the 5.0 calls for Oct and Nov hoping for them to go out worthless, but even if not, it will be profit if I am called out anywhere in the money. In this market you need to take profits as they come, and writing the options can be good. I would even consider writing the $5 puts, though all of this takes valuable margin so need to be prudent.
PennyStockTrader2
3 years ago
wow DRIO has really tanked, imagine from the 30s down to 5 dollar range, wow. I have done some trading and have an average around 7.50 since first purchase at 12.65, not bad, but you can never pick the bottom of any of these they always go further than you think is possible, I am fine with that. DRIO at 6 bucks is a great price.
whytestocks
4 years ago
News: $DRIO NetworkNewsBreaks - Shares of DarioHealth Corp. (NASDAQ: DRIO) Reach 52-Week High
Shares of DarioHealth Corp. (NASDAQ: DRIO) , a pioneer in the global digital therapeutics market, reached a new 52-week high on Wednesday. In morning trading, the company’s shares reached a peak of $22.49 on volume of over 170,000, up from an opening price of $18.75. At time of publish...
Read the whole news DRIO - NetworkNewsBreaks - Shares of DarioHealth Corp. (NASDAQ: DRIO) Reach 52-Week High
whytestocks
4 years ago
News: $DRIO DarioHealth Announces $28.6 Million Private Placement
NEW YORK , July 31, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that it closed a private placement transaction with accredited investors, including healthcare funds and institutions from the U.S. and Israel ....
In case you are interested DRIO - DarioHealth Announces $28.6 Million Private Placement